#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Atherosclerosis is a common pathology that affects large and medium arteries leading to a variety of cardiovascular events that can also be fatal , therefore representing a serious public health problem .
2-1	16-31	Atherosclerosis	abstract	new	coref	2-3[3_0]
2-2	32-34	is	_	_	_	_
2-3	35-36	a	abstract[3]	giv[3]	coref	3-1[0_3]
2-4	37-43	common	abstract[3]	giv[3]	_	_
2-5	44-53	pathology	abstract[3]	giv[3]	_	_
2-6	54-58	that	_	_	_	_
2-7	59-66	affects	_	_	_	_
2-8	67-72	large	object[4]	new[4]	_	_
2-9	73-76	and	object[4]	new[4]	_	_
2-10	77-83	medium	object[4]	new[4]	_	_
2-11	84-92	arteries	object[4]	new[4]	_	_
2-12	93-100	leading	_	_	_	_
2-13	101-103	to	_	_	_	_
2-14	104-105	a	event[5]	new[5]	_	_
2-15	106-113	variety	event[5]	new[5]	_	_
2-16	114-116	of	event[5]	new[5]	_	_
2-17	117-131	cardiovascular	event[5]|event[6]	new[5]|new[6]	coref	5-16[29_6]
2-18	132-138	events	event[5]|event[6]	new[5]|new[6]	_	_
2-19	139-143	that	_	_	_	_
2-20	144-147	can	_	_	_	_
2-21	148-152	also	_	_	_	_
2-22	153-155	be	_	_	_	_
2-23	156-161	fatal	_	_	_	_
2-24	162-163	,	_	_	_	_
2-25	164-173	therefore	_	_	_	_
2-26	174-186	representing	_	_	_	_
2-27	187-188	a	abstract[8]	new[8]	_	_
2-28	189-196	serious	abstract[8]	new[8]	_	_
2-29	197-203	public	abstract[8]	new[8]	_	_
2-30	204-210	health	abstract|abstract[8]	new|new[8]	_	_
2-31	211-218	problem	abstract[8]	new[8]	_	_
2-32	219-220	.	_	_	_	_

#Text=Atherosclerosis is characterized by progressive lipid deposition in the arterial wall , plaque induction and possible further progression to the state of so-called unstable plaque .
3-1	221-236	Atherosclerosis	abstract	giv	coref	7-13
3-2	237-239	is	_	_	_	_
3-3	240-253	characterized	_	_	_	_
3-4	254-256	by	_	_	_	_
3-5	257-268	progressive	event[11]	new[11]	_	_
3-6	269-274	lipid	person|event[11]	new|new[11]	coref	14-10
3-7	275-285	deposition	event[11]	new[11]	_	_
3-8	286-288	in	event[11]	new[11]	_	_
3-9	289-292	the	event[11]|object[12]	new[11]|new[12]	_	_
3-10	293-301	arterial	event[11]|object[12]	new[11]|new[12]	_	_
3-11	302-306	wall	event[11]|object[12]	new[11]|new[12]	_	_
3-12	307-308	,	event[11]	new[11]	_	_
3-13	309-315	plaque	event[11]|object|event[14]	new[11]|new|new[14]	coref|coref	3-23[17_0]|3-23[17_0]
3-14	316-325	induction	event[11]|event[14]	new[11]|new[14]	_	_
3-15	326-329	and	event[11]	new[11]	_	_
3-16	330-338	possible	event[11]|event[15]	new[11]|new[15]	coref	17-14[0_15]
3-17	339-346	further	event[11]|event[15]	new[11]|new[15]	_	_
3-18	347-358	progression	event[11]|event[15]	new[11]|new[15]	_	_
3-19	359-361	to	event[11]|event[15]	new[11]|new[15]	_	_
3-20	362-365	the	event[11]|event[15]|abstract[16]	new[11]|new[15]|new[16]	_	_
3-21	366-371	state	event[11]|event[15]|abstract[16]	new[11]|new[15]|new[16]	_	_
3-22	372-374	of	event[11]|event[15]|abstract[16]	new[11]|new[15]|new[16]	_	_
3-23	375-384	so-called	event[11]|event[15]|abstract[16]|object[17]	new[11]|new[15]|new[16]|giv[17]	coref	4-10[20_17]
3-24	385-393	unstable	event[11]|event[15]|abstract[16]|object[17]	new[11]|new[15]|new[16]|giv[17]	_	_
3-25	394-400	plaque	event[11]|event[15]|abstract[16]|object[17]	new[11]|new[15]|new[16]|giv[17]	_	_
3-26	401-402	.	_	_	_	_

#Text=Advanced plaques usually acquire a fibrous cap that separates the plaque from the surrounding milieu and plays a stabilizing role .
4-1	403-411	Advanced	object[18]	new[18]	coref	5-3[0_18]
4-2	412-419	plaques	object[18]	new[18]	_	_
4-3	420-427	usually	_	_	_	_
4-4	428-435	acquire	_	_	_	_
4-5	436-437	a	object[19]	new[19]	_	_
4-6	438-445	fibrous	object[19]	new[19]	_	_
4-7	446-449	cap	object[19]	new[19]	_	_
4-8	450-454	that	_	_	_	_
4-9	455-464	separates	_	_	_	_
4-10	465-468	the	object[20]	giv[20]	coref	6-19[0_20]
4-11	469-475	plaque	object[20]	giv[20]	_	_
4-12	476-480	from	_	_	_	_
4-13	481-484	the	abstract[21]	new[21]	_	_
4-14	485-496	surrounding	abstract[21]	new[21]	_	_
4-15	497-503	milieu	abstract[21]	new[21]	_	_
4-16	504-507	and	_	_	_	_
4-17	508-513	plays	_	_	_	_
4-18	514-515	a	abstract[22]	new[22]	coref	9-7[53_22]
4-19	516-527	stabilizing	abstract[22]	new[22]	_	_
4-20	528-532	role	abstract[22]	new[22]	_	_
4-21	533-534	.	_	_	_	_

#Text=Destabilization of plaques leads to their rupture with subsequent thrombus formation that can lead to dangerous events such as acute coronary syndrome ( ACS ) and stroke .
5-1	535-550	Destabilization	abstract[23]	new[23]	_	_
5-2	551-553	of	abstract[23]	new[23]	_	_
5-3	554-561	plaques	abstract[23]|object	new[23]|giv	ana	5-6
5-4	562-567	leads	_	_	_	_
5-5	568-570	to	_	_	_	_
5-6	571-576	their	object|event[26]	giv|new[26]	coref|coref	6-1[34_0]|6-1[34_0]
5-7	577-584	rupture	event[26]	new[26]	_	_
5-8	585-589	with	event[26]	new[26]	_	_
5-9	590-600	subsequent	event[26]|event[28]	new[26]|new[28]	coref	6-8[35_28]
5-10	601-609	thrombus	event[26]|abstract|event[28]	new[26]|new|new[28]	_	_
5-11	610-619	formation	event[26]|event[28]	new[26]|new[28]	_	_
5-12	620-624	that	_	_	_	_
5-13	625-628	can	_	_	_	_
5-14	629-633	lead	_	_	_	_
5-15	634-636	to	_	_	_	_
5-16	637-646	dangerous	event[29]	giv[29]	_	_
5-17	647-653	events	event[29]	giv[29]	_	_
5-18	654-658	such	event[29]	giv[29]	_	_
5-19	659-661	as	event[29]	giv[29]	_	_
5-20	662-667	acute	event[29]|abstract[31]	giv[29]|new[31]	appos	5-24[0_31]
5-21	668-676	coronary	event[29]|person|abstract[31]	giv[29]|new|new[31]	_	_
5-22	677-685	syndrome	event[29]|abstract[31]	giv[29]|new[31]	_	_
5-23	686-687	(	_	_	_	_
5-24	688-691	ACS	abstract	giv	_	_
5-25	692-693	)	_	_	_	_
5-26	694-697	and	_	_	_	_
5-27	698-704	stroke	event	new	_	_
5-28	705-706	.	_	_	_	_

#Text=Advanced complicated plaques are also characterized by the formation of the necrotic core , pathological vascular remodeling , plaque neovascularization and calcification .
6-1	707-715	Advanced	object[34]	giv[34]	coref	7-25[46_34]
6-2	716-727	complicated	object[34]	giv[34]	_	_
6-3	728-735	plaques	object[34]	giv[34]	_	_
6-4	736-739	are	_	_	_	_
6-5	740-744	also	_	_	_	_
6-6	745-758	characterized	_	_	_	_
6-7	759-761	by	_	_	_	_
6-8	762-765	the	event[35]	giv[35]	_	_
6-9	766-775	formation	event[35]	giv[35]	_	_
6-10	776-778	of	event[35]	giv[35]	_	_
6-11	779-782	the	event[35]|abstract[36]	giv[35]|new[36]	_	_
6-12	783-791	necrotic	event[35]|abstract[36]	giv[35]|new[36]	_	_
6-13	792-796	core	event[35]|abstract[36]	giv[35]|new[36]	_	_
6-14	797-798	,	event[35]	giv[35]	_	_
6-15	799-811	pathological	event[35]|abstract[37]	giv[35]|new[37]	_	_
6-16	812-820	vascular	event[35]|abstract[37]	giv[35]|new[37]	_	_
6-17	821-831	remodeling	event[35]|abstract[37]	giv[35]|new[37]	_	_
6-18	832-833	,	event[35]	giv[35]	_	_
6-19	834-840	plaque	event[35]|object|abstract[39]	giv[35]|giv|new[39]	coref|coref	15-14[114_0]|15-14[114_0]
6-20	841-859	neovascularization	event[35]|abstract[39]	giv[35]|new[39]	_	_
6-21	860-863	and	event[35]	giv[35]	_	_
6-22	864-877	calcification	event[35]|abstract	giv[35]|new	_	_
6-23	878-879	.	_	_	_	_

#Text=Elevated low-density lipoprotein ( LDL ) is known to be associated with atherosclerosis and is identified as the major source of lipids accumulating in atherosclerotic plaques .
7-1	880-888	Elevated	substance[41]	new[41]	_	_
7-2	889-900	low-density	substance[41]	new[41]	_	_
7-3	901-912	lipoprotein	substance[41]	new[41]	_	_
7-4	913-914	(	_	_	_	_
7-5	915-918	LDL	abstract	new	coref	8-2[47_0]
7-6	919-920	)	_	_	_	_
7-7	921-923	is	_	_	_	_
7-8	924-929	known	_	_	_	_
7-9	930-932	to	_	_	_	_
7-10	933-935	be	_	_	_	_
7-11	936-946	associated	_	_	_	_
7-12	947-951	with	_	_	_	_
7-13	952-967	atherosclerosis	abstract	giv	coref	9-11
7-14	968-971	and	_	_	_	_
7-15	972-974	is	_	_	_	_
7-16	975-985	identified	_	_	_	_
7-17	986-988	as	_	_	_	_
7-18	989-992	the	_	_	_	_
7-19	993-998	major	_	_	_	_
7-20	999-1005	source	_	_	_	_
7-21	1006-1008	of	_	_	_	_
7-22	1009-1015	lipids	substance	new	_	_
7-23	1016-1028	accumulating	_	_	_	_
7-24	1029-1031	in	_	_	_	_
7-25	1032-1047	atherosclerotic	substance|object[46]	new|giv[46]	_	_
7-26	1048-1055	plaques	object[46]	giv[46]	_	_
7-27	1056-1057	.	_	_	_	_

#Text=Circulating modified LDL has increased atherogenicity in comparison to native LDL .
8-1	1058-1069	Circulating	_	_	_	_
8-2	1070-1078	modified	abstract[47]	giv[47]	coref	8-10[50_47]
8-3	1079-1082	LDL	abstract[47]	giv[47]	_	_
8-4	1083-1086	has	_	_	_	_
8-5	1087-1096	increased	_	_	_	_
8-6	1097-1111	atherogenicity	abstract	new	_	_
8-7	1112-1114	in	_	_	_	_
8-8	1115-1125	comparison	abstract[49]	new[49]	_	_
8-9	1126-1128	to	abstract[49]	new[49]	_	_
8-10	1129-1135	native	abstract[49]|abstract[50]	new[49]|giv[50]	coref	9-4[0_50]
8-11	1136-1139	LDL	abstract[49]|abstract[50]	new[49]|giv[50]	_	_
8-12	1140-1141	.	_	_	_	_

#Text=Chemical modification of LDL likely plays a prominent role in atherosclerosis development .
9-1	1142-1150	Chemical	abstract[51]	new[51]	_	_
9-2	1151-1163	modification	abstract[51]	new[51]	_	_
9-3	1164-1166	of	abstract[51]	new[51]	_	_
9-4	1167-1170	LDL	abstract[51]|substance	new[51]|giv	coref	10-3
9-5	1171-1177	likely	_	_	_	_
9-6	1178-1183	plays	_	_	_	_
9-7	1184-1185	a	abstract[53]	giv[53]	_	_
9-8	1186-1195	prominent	abstract[53]	giv[53]	_	_
9-9	1196-1200	role	abstract[53]	giv[53]	_	_
9-10	1201-1203	in	abstract[53]	giv[53]	_	_
9-11	1204-1219	atherosclerosis	abstract[53]|abstract|abstract[55]	giv[53]|giv|new[55]	coref|coref	13-22|13-22
9-12	1220-1231	development	abstract[53]|abstract[55]	giv[53]|new[55]	_	_
9-13	1232-1233	.	_	_	_	_

#Text=Besides elevated LDL , chronic inflammation is now considered as another crucial pro-atherogenic mechanism that can even precede lipid entry into the arterial intima .
10-1	1234-1241	Besides	_	_	_	_
10-2	1242-1250	elevated	_	_	_	_
10-3	1251-1254	LDL	abstract	giv	_	_
10-4	1255-1256	,	_	_	_	_
10-5	1257-1264	chronic	abstract[57]	new[57]	ana	11-1[0_57]
10-6	1265-1277	inflammation	abstract[57]	new[57]	_	_
10-7	1278-1280	is	_	_	_	_
10-8	1281-1284	now	_	_	_	_
10-9	1285-1295	considered	_	_	_	_
10-10	1296-1298	as	_	_	_	_
10-11	1299-1306	another	_	_	_	_
10-12	1307-1314	crucial	_	_	_	_
10-13	1315-1330	pro-atherogenic	_	_	_	_
10-14	1331-1340	mechanism	_	_	_	_
10-15	1341-1345	that	_	_	_	_
10-16	1346-1349	can	_	_	_	_
10-17	1350-1354	even	_	_	_	_
10-18	1355-1362	precede	_	_	_	_
10-19	1363-1368	lipid	abstract|place[59]	new|new[59]	coref|coref	14-6|14-6
10-20	1369-1374	entry	place[59]	new[59]	_	_
10-21	1375-1379	into	_	_	_	_
10-22	1380-1383	the	place[60]	new[60]	_	_
10-23	1384-1392	arterial	place[60]	new[60]	_	_
10-24	1393-1399	intima	place[60]	new[60]	_	_
10-25	1400-1401	.	_	_	_	_

#Text=It has been proposed that disturbances of hemodynamic forces that are especially likely to occur at atheroprone sites of blood vessels , such as bends or bifurcations , can cause local activation of endothelial cells ( ECs ) .
11-1	1402-1404	It	abstract	giv	coref	13-16
11-2	1405-1408	has	_	_	_	_
11-3	1409-1413	been	_	_	_	_
11-4	1414-1422	proposed	_	_	_	_
11-5	1423-1427	that	_	_	_	_
11-6	1428-1440	disturbances	abstract[62]	new[62]	_	_
11-7	1441-1443	of	abstract[62]	new[62]	_	_
11-8	1444-1455	hemodynamic	abstract[62]|abstract[63]	new[62]|new[63]	_	_
11-9	1456-1462	forces	abstract[62]|abstract[63]	new[62]|new[63]	_	_
11-10	1463-1467	that	_	_	_	_
11-11	1468-1471	are	_	_	_	_
11-12	1472-1482	especially	_	_	_	_
11-13	1483-1489	likely	_	_	_	_
11-14	1490-1492	to	_	_	_	_
11-15	1493-1498	occur	_	_	_	_
11-16	1499-1501	at	_	_	_	_
11-17	1502-1513	atheroprone	place[64]	new[64]	_	_
11-18	1514-1519	sites	place[64]	new[64]	_	_
11-19	1520-1522	of	place[64]	new[64]	_	_
11-20	1523-1528	blood	place[64]|object[65]	new[64]|new[65]	_	_
11-21	1529-1536	vessels	place[64]|object[65]	new[64]|new[65]	_	_
11-22	1537-1538	,	place[64]|object[65]	new[64]|new[65]	_	_
11-23	1539-1543	such	place[64]|object[65]	new[64]|new[65]	_	_
11-24	1544-1546	as	place[64]|object[65]	new[64]|new[65]	_	_
11-25	1547-1552	bends	place[64]|object[65]|event	new[64]|new[65]|new	_	_
11-26	1553-1555	or	place[64]|object[65]	new[64]|new[65]	_	_
11-27	1556-1568	bifurcations	place[64]|object[65]|abstract	new[64]|new[65]|new	_	_
11-28	1569-1570	,	_	_	_	_
11-29	1571-1574	can	_	_	_	_
11-30	1575-1580	cause	_	_	_	_
11-31	1581-1586	local	abstract[68]	new[68]	_	_
11-32	1587-1597	activation	abstract[68]	new[68]	_	_
11-33	1598-1600	of	abstract[68]	new[68]	_	_
11-34	1601-1612	endothelial	abstract[68]|object[69]	new[68]|new[69]	appos	11-37[0_69]
11-35	1613-1618	cells	abstract[68]|object[69]	new[68]|new[69]	_	_
11-36	1619-1620	(	_	_	_	_
11-37	1621-1624	ECs	object	giv	coref	12-3
11-38	1625-1626	)	_	_	_	_
11-39	1627-1628	.	_	_	_	_

#Text=Consequently , ECs acquire a pro-inflammatory phenotype and start expressing different pro-inflammatory molecules , such as monocyte chemotactic protein 1 ( MCP1 ) ( also known as chemokine ( C-C motif ) ligand 2 ; CCL2 ) , intercellular adhesion molecule 1 ( ICAM-1 ) and vascular cell adhesion molecule 1 ( VCAM-1 ) , all of which attract monocytes to the activated endothelium .
12-1	1629-1641	Consequently	_	_	_	_
12-2	1642-1643	,	_	_	_	_
12-3	1644-1647	ECs	object	giv	coref	14-16[103_0]
12-4	1648-1655	acquire	_	_	_	_
12-5	1656-1657	a	abstract[72]	new[72]	coref	13-7[92_72]
12-6	1658-1674	pro-inflammatory	abstract[72]	new[72]	_	_
12-7	1675-1684	phenotype	abstract[72]	new[72]	_	_
12-8	1685-1688	and	_	_	_	_
12-9	1689-1694	start	_	_	_	_
12-10	1695-1705	expressing	_	_	_	_
12-11	1706-1715	different	substance[73]	new[73]	_	_
12-12	1716-1732	pro-inflammatory	substance[73]	new[73]	_	_
12-13	1733-1742	molecules	substance[73]	new[73]	_	_
12-14	1743-1744	,	substance[73]	new[73]	_	_
12-15	1745-1749	such	substance[73]	new[73]	_	_
12-16	1750-1752	as	substance[73]	new[73]	_	_
12-17	1753-1761	monocyte	substance[73]|substance[75]	new[73]|new[75]	_	_
12-18	1762-1773	chemotactic	substance[73]|abstract|substance[75]	new[73]|new|new[75]	_	_
12-19	1774-1781	protein	substance[73]|substance[75]	new[73]|new[75]	_	_
12-20	1782-1783	1	substance[73]|substance[75]	new[73]|new[75]	_	_
12-21	1784-1785	(	substance[73]|substance[75]	new[73]|new[75]	_	_
12-22	1786-1790	MCP1	substance[73]|substance[75]|object	new[73]|new[75]|new	_	_
12-23	1791-1792	)	substance[73]|substance[75]	new[73]|new[75]	_	_
12-24	1793-1794	(	_	_	_	_
12-25	1795-1799	also	_	_	_	_
12-26	1800-1805	known	_	_	_	_
12-27	1806-1808	as	_	_	_	_
12-28	1809-1818	chemokine	_	_	_	_
12-29	1819-1820	(	_	_	_	_
12-30	1821-1824	C-C	abstract|abstract[78]	new|new[78]	_	_
12-31	1825-1830	motif	abstract[78]	new[78]	_	_
12-32	1831-1832	)	_	_	_	_
12-33	1833-1839	ligand	abstract[79]	new[79]	appos	12-36[0_79]
12-34	1840-1841	2	abstract[79]	new[79]	_	_
12-35	1842-1843	;	_	_	_	_
12-36	1844-1848	CCL2	abstract	giv	_	_
12-37	1849-1850	)	_	_	_	_
12-38	1851-1852	,	_	_	_	_
12-39	1853-1866	intercellular	_	_	_	_
12-40	1867-1875	adhesion	substance	new	coref	12-48[84_0]
12-41	1876-1884	molecule	_	_	_	_
12-42	1885-1886	1	_	_	_	_
12-43	1887-1888	(	_	_	_	_
12-44	1889-1895	ICAM-1	event	new	ana	12-56[86_0]
12-45	1896-1897	)	_	_	_	_
12-46	1898-1901	and	_	_	_	_
12-47	1902-1910	vascular	_	_	_	_
12-48	1911-1915	cell	place|substance[84]	new|giv[84]	_	_
12-49	1916-1924	adhesion	substance[84]	giv[84]	_	_
12-50	1925-1933	molecule	_	_	_	_
12-51	1934-1935	1	_	_	_	_
12-52	1936-1937	(	_	_	_	_
12-53	1938-1944	VCAM-1	object	new	_	_
12-54	1945-1946	)	_	_	_	_
12-55	1947-1948	,	_	_	_	_
12-56	1949-1952	all	event[86]	giv[86]	_	_
12-57	1953-1955	of	event[86]	giv[86]	_	_
12-58	1956-1961	which	event[86]	giv[86]	_	_
12-59	1962-1969	attract	_	_	_	_
12-60	1970-1979	monocytes	object	new	_	_
12-61	1980-1982	to	_	_	_	_
12-62	1983-1986	the	place[88]	new[88]	_	_
12-63	1987-1996	activated	place[88]	new[88]	_	_
12-64	1997-2008	endothelium	place[88]	new[88]	_	_
12-65	2009-2010	.	_	_	_	_

#Text=The imbalance of monocyte/macrophage polarization towards the preferential pro-inflammatory phenotype and a lack of normal inflammation resolution are also present in atherosclerosis .
13-1	2011-2014	The	abstract[89]	new[89]	_	_
13-2	2015-2024	imbalance	abstract[89]	new[89]	_	_
13-3	2025-2027	of	abstract[89]	new[89]	_	_
13-4	2028-2047	monocyte/macrophage	abstract[89]|place|abstract[91]	new[89]|new|new[91]	_	_
13-5	2048-2060	polarization	abstract[89]|abstract[91]	new[89]|new[91]	_	_
13-6	2061-2068	towards	abstract[89]|abstract[91]	new[89]|new[91]	_	_
13-7	2069-2072	the	abstract[89]|abstract[91]|abstract[92]	new[89]|new[91]|giv[92]	_	_
13-8	2073-2085	preferential	abstract[89]|abstract[91]|abstract[92]	new[89]|new[91]|giv[92]	_	_
13-9	2086-2102	pro-inflammatory	abstract[89]|abstract[91]|abstract[92]	new[89]|new[91]|giv[92]	_	_
13-10	2103-2112	phenotype	abstract[89]|abstract[91]|abstract[92]	new[89]|new[91]|giv[92]	_	_
13-11	2113-2116	and	_	_	_	_
13-12	2117-2118	a	abstract[93]	new[93]	_	_
13-13	2119-2123	lack	abstract[93]	new[93]	_	_
13-14	2124-2126	of	abstract[93]	new[93]	_	_
13-15	2127-2133	normal	abstract[93]|abstract[95]	new[93]|new[95]	coref	15-6[112_95]
13-16	2134-2146	inflammation	abstract[93]|abstract|abstract[95]	new[93]|giv|new[95]	_	_
13-17	2147-2157	resolution	abstract[93]|abstract[95]	new[93]|new[95]	_	_
13-18	2158-2161	are	_	_	_	_
13-19	2162-2166	also	_	_	_	_
13-20	2167-2174	present	_	_	_	_
13-21	2175-2177	in	_	_	_	_
13-22	2178-2193	atherosclerosis	abstract	giv	coref	17-11
13-23	2194-2195	.	_	_	_	_

#Text=Phagocytic macrophages actively participate in lipid accumulation by engulfing lipid droplets and give rise to foam cells . Dendritic cells ( DCs ) contribute to the local inflammatory response through antigen presentation and cytokine signaling processes .
14-1	2196-2206	Phagocytic	object[97]	new[97]	_	_
14-2	2207-2218	macrophages	object[97]	new[97]	_	_
14-3	2219-2227	actively	_	_	_	_
14-4	2228-2239	participate	_	_	_	_
14-5	2240-2242	in	_	_	_	_
14-6	2243-2248	lipid	abstract|abstract[99]	giv|new[99]	_	_
14-7	2249-2261	accumulation	abstract[99]	new[99]	_	_
14-8	2262-2264	by	_	_	_	_
14-9	2265-2274	engulfing	_	_	_	_
14-10	2275-2280	lipid	person|object[101]	giv|new[101]	_	_
14-11	2281-2289	droplets	object[101]	new[101]	_	_
14-12	2290-2293	and	_	_	_	_
14-13	2294-2298	give	_	_	_	_
14-14	2299-2303	rise	event	new	_	_
14-15	2304-2306	to	_	_	_	_
14-16	2307-2311	foam	object[103]	giv[103]	coref	14-19[104_103]
14-17	2312-2317	cells	object[103]	giv[103]	_	_
14-18	2318-2319	.	_	_	_	_
14-19	2320-2329	Dendritic	object[104]	giv[104]	coref	17-6[121_104]
14-20	2330-2335	cells	object[104]	giv[104]	_	_
14-21	2336-2337	(	_	_	_	_
14-22	2338-2341	DCs	organization	new	_	_
14-23	2342-2343	)	_	_	_	_
14-24	2344-2354	contribute	_	_	_	_
14-25	2355-2357	to	_	_	_	_
14-26	2358-2361	the	abstract[106]	new[106]	coref	16-6[116_106]
14-27	2362-2367	local	abstract[106]	new[106]	_	_
14-28	2368-2380	inflammatory	abstract[106]	new[106]	_	_
14-29	2381-2389	response	abstract[106]	new[106]	_	_
14-30	2390-2397	through	abstract[106]	new[106]	_	_
14-31	2398-2405	antigen	abstract[106]|substance|abstract[108]	new[106]|new|new[108]	_	_
14-32	2406-2418	presentation	abstract[106]|abstract[108]	new[106]|new[108]	_	_
14-33	2419-2422	and	abstract[106]	new[106]	_	_
14-34	2423-2431	cytokine	abstract[106]|abstract|abstract[110]	new[106]|new|new[110]	coref|coref	15-10[0_110]|15-10[0_110]
14-35	2432-2441	signaling	abstract[106]|abstract[110]	new[106]|new[110]	_	_
14-36	2442-2451	processes	abstract[106]|abstract[110]	new[106]|new[110]	_	_
14-37	2452-2453	.	_	_	_	_

#Text=If the inflammatory process reaches a resolution , repair processes begin , and the plaque can become stable .
15-1	2454-2456	If	_	_	_	_
15-2	2457-2460	the	abstract[111]	new[111]	_	_
15-3	2461-2473	inflammatory	abstract[111]	new[111]	_	_
15-4	2474-2481	process	abstract[111]	new[111]	_	_
15-5	2482-2489	reaches	_	_	_	_
15-6	2490-2491	a	abstract[112]	giv[112]	_	_
15-7	2492-2502	resolution	abstract[112]	giv[112]	_	_
15-8	2503-2504	,	_	_	_	_
15-9	2505-2511	repair	_	_	_	_
15-10	2512-2521	processes	abstract	giv	_	_
15-11	2522-2527	begin	_	_	_	_
15-12	2528-2529	,	_	_	_	_
15-13	2530-2533	and	_	_	_	_
15-14	2534-2537	the	object[114]	giv[114]	coref	16-15[118_114]
15-15	2538-2544	plaque	object[114]	giv[114]	_	_
15-16	2545-2548	can	_	_	_	_
15-17	2549-2555	become	_	_	_	_
15-18	2556-2562	stable	_	_	_	_
15-19	2563-2564	.	_	_	_	_

#Text=However , failure to resolve the inflammatory response can result in the formation of the most dangerous unstable plaque that can cause thrombosis .
16-1	2565-2572	However	_	_	_	_
16-2	2573-2574	,	_	_	_	_
16-3	2575-2582	failure	event	new	_	_
16-4	2583-2585	to	_	_	_	_
16-5	2586-2593	resolve	_	_	_	_
16-6	2594-2597	the	abstract[116]	giv[116]	_	_
16-7	2598-2610	inflammatory	abstract[116]	giv[116]	_	_
16-8	2611-2619	response	abstract[116]	giv[116]	_	_
16-9	2620-2623	can	_	_	_	_
16-10	2624-2630	result	_	_	_	_
16-11	2631-2633	in	_	_	_	_
16-12	2634-2637	the	event[117]	new[117]	_	_
16-13	2638-2647	formation	event[117]	new[117]	_	_
16-14	2648-2650	of	event[117]	new[117]	_	_
16-15	2651-2654	the	event[117]|object[118]	new[117]|giv[118]	_	_
16-16	2655-2659	most	event[117]|object[118]	new[117]|giv[118]	_	_
16-17	2660-2669	dangerous	event[117]|object[118]	new[117]|giv[118]	_	_
16-18	2670-2678	unstable	event[117]|object[118]	new[117]|giv[118]	_	_
16-19	2679-2685	plaque	event[117]|object[118]	new[117]|giv[118]	_	_
16-20	2686-2690	that	_	_	_	_
16-21	2691-2694	can	_	_	_	_
16-22	2695-2700	cause	_	_	_	_
16-23	2701-2711	thrombosis	event	new	_	_
16-24	2712-2713	.	_	_	_	_

#Text=Therefore , a variety of immune cells are involved in atherosclerosis initiation and progression .
17-1	2714-2723	Therefore	_	_	_	_
17-2	2724-2725	,	_	_	_	_
17-3	2726-2727	a	abstract[120]	new[120]	_	_
17-4	2728-2735	variety	abstract[120]	new[120]	_	_
17-5	2736-2738	of	abstract[120]	new[120]	_	_
17-6	2739-2745	immune	abstract[120]|object[121]	new[120]|giv[121]	coref	18-10[128_121]
17-7	2746-2751	cells	abstract[120]|object[121]	new[120]|giv[121]	_	_
17-8	2752-2755	are	_	_	_	_
17-9	2756-2764	involved	_	_	_	_
17-10	2765-2767	in	_	_	_	_
17-11	2768-2783	atherosclerosis	abstract|abstract[123]	giv|new[123]	_	_
17-12	2784-2794	initiation	abstract[123]	new[123]	_	_
17-13	2795-2798	and	_	_	_	_
17-14	2799-2810	progression	event	giv	_	_
17-15	2811-2812	.	_	_	_	_

#Text=In this review , we consider main subsets of pro- and anti-inflammatory immune cells of myeloid origin that contribute to atherogenesis .
18-1	2813-2815	In	_	_	_	_
18-2	2816-2820	this	abstract[125]	new[125]	_	_
18-3	2821-2827	review	abstract[125]	new[125]	_	_
18-4	2828-2829	,	_	_	_	_
18-5	2830-2832	we	person	acc	_	_
18-6	2833-2841	consider	_	_	_	_
18-7	2842-2846	main	abstract[127]	new[127]	_	_
18-8	2847-2854	subsets	abstract[127]	new[127]	_	_
18-9	2855-2857	of	abstract[127]	new[127]	_	_
18-10	2858-2862	pro-	abstract[127]|object[128]	new[127]|giv[128]	_	_
18-11	2863-2866	and	abstract[127]|object[128]	new[127]|giv[128]	_	_
18-12	2867-2884	anti-inflammatory	abstract[127]|object[128]	new[127]|giv[128]	_	_
18-13	2885-2891	immune	abstract[127]|object[128]	new[127]|giv[128]	_	_
18-14	2892-2897	cells	abstract[127]|object[128]	new[127]|giv[128]	_	_
18-15	2898-2900	of	abstract[127]|object[128]	new[127]|giv[128]	_	_
18-16	2901-2908	myeloid	abstract[127]|object[128]|place|abstract[130]	new[127]|giv[128]|new|new[130]	_	_
18-17	2909-2915	origin	abstract[127]|object[128]|abstract[130]	new[127]|giv[128]|new[130]	_	_
18-18	2916-2920	that	_	_	_	_
18-19	2921-2931	contribute	_	_	_	_
18-20	2932-2934	to	_	_	_	_
18-21	2935-2948	atherogenesis	abstract	new	_	_
18-22	2949-2950	.	_	_	_	_
